News for China Medical System Holdings Limited (0867.HK)

SHENZHEN, CHINA, Feb. 14, 2025 (GLOBE NEWSWIRE) --  In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited ('CMS” or the 'Group”) has been included in the S&P Global Sustainability Yearbook 2025 (the 'Yearbook 2025”). This marks the Group's first inclusion in the global edition of S&P Global Sustainability Yearbook (the 'Yearbook”), following the S&P Global Sustainability Yearbook (China Edition) inclusion for consecutive two years.

SHENZHEN, CHINA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the 'Company”, together with its subsidiaries, the 'Group” or 'CMS”) is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement  (the 'Agreement”)  with Alpha Cognition Inc. ('Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）('ZUNVEY” or  the 'Product”)  for the treatment of mild-to-moderate dementia of the Alzheimer's type. The Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan), Australia and New Zealand (the 'Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years, which may be automatically renewed every five years upon the expiration unless terminated by notice from either party.

SHENZHEN, CHINA, Dec. 08, 2024 (GLOBE NEWSWIRE) -- On 6 December, China Medical System Holdings Limited ('CMS” or the 'Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the 'Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopies.

China Medical System：First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area

SHENZHEN, CHINA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18...

SHENZHEN, CHINA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or...

China Medical System （00867） Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023

CMS enters the

SHENZHEN, CHINA, Aug. 05, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or...

China Medical System （867.HK） Reincluded in S&P Global Sustainability Yearbook （China Edition） and Maintained MSCI ESG AA Rating